Home » Industry: Biosimilar Review Goals ‘Not Sufficiently Aggressive’
Industry: Biosimilar Review Goals ‘Not Sufficiently Aggressive’
As the FDA and biosimilar makers start negotiations to develop a user fee program, several areas of disagreement are coming to light, including how to phase in performance goals for the agency.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
07May
-
14May
-
30May